Ultrasensitive antigen tests are needed for early detection of numerous infectious diseases, and for surveillance and monitoring progress towards disease elimination. GHIG and IDC/LSHTM worked with the Global Good Fund and Intellectual Ventures Laboratory to understand how to improve and expand LFA technologies to a wide range of infectious and potentially non-infectious diseases with high burden in low-and middle-income countries; particularly for the neglected tropical diseases (NTDs).
